RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Astellas Pharma Stock

Astellas Pharma Liabilities 2024

Astellas Pharma Liabilities

1.97 T JPY

Ticker

4503.T

ISIN

JP3942400007

WKN

856273

In 2024, Astellas Pharma's total liabilities amounted to 1.97 T JPY, a 126.31% difference from the 872.09 B JPY total liabilities in the previous year.

Astellas Pharma Aktienanalyse

What does Astellas Pharma do?

Astellas Pharma Inc. is a global pharmaceutical company based in Tokyo, Japan. The company manufactures and distributes medications worldwide. It was formed in April 2005 through the merger of two well-known Japanese pharmaceutical companies - Yamanouchi and Fujisawa. This merger created one of Japan's largest pharmaceutical companies and allowed for collaboration on the global market and the development of new innovations in medication research. Astellas' business model is focused on targeted research and development, comprehensive marketing and distribution networks, and collaboration with international partners. The company's main areas of focus are cancer, urology, transplantation, anti-infectives, and pneumology. Astellas has expanded its business through acquisitions and partnerships and currently operates in over 50 countries worldwide. In addition to pharmaceutical production, the company also provides services and consulting in the medical and health sectors. Astellas' business is divided into segments including pharmaceuticals, medical devices, and diagnostics. The pharmaceutical segment is the largest and offers a wide range of prescription medications for various medical areas. The medical devices segment specializes in the development and manufacturing of medical devices such as catheters, stents, and heart valves. The diagnostics segment focuses on developing and producing testing systems and instruments for diseases such as HIV and infectious diseases. Overall, Astellas is an important player in the global pharmaceutical and health industry, known for its innovative research, wide range of products, and collaboration with partners to develop campaigns against various diseases. Astellas Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Astellas Pharma's Liabilities

Astellas Pharma's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Astellas Pharma's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Astellas Pharma's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Astellas Pharma's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Astellas Pharma’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Astellas Pharma stock

What is the level of liabilities of Astellas Pharma this year?

Astellas Pharma has a debt balance of 1.97 T JPY this year.

What were the liabilities of Astellas Pharma compared to the previous year?

The liabilities of Astellas Pharma have increased by 126.31% increased compared to the previous year.

What are the consequences of high debt for investors of Astellas Pharma?

High liabilities can pose a risk for investors of Astellas Pharma, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Astellas Pharma?

Low liabilities mean that Astellas Pharma has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Astellas Pharma affect the company?

An increase in liabilities of Astellas Pharma can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Astellas Pharma affect the company?

A decrease in the liabilities of Astellas Pharma can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Astellas Pharma?

Some factors that can influence the liabilities of Astellas Pharma include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Astellas Pharma so important for investors?

The liabilities of Astellas Pharma are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Astellas Pharma take to modify the liabilities?

To change its liabilities, Astellas Pharma can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Astellas Pharma pay?

Over the past 12 months, Astellas Pharma paid a dividend of 72 JPY . This corresponds to a dividend yield of about 4.67 %. For the coming 12 months, Astellas Pharma is expected to pay a dividend of 73.66 JPY.

What is the dividend yield of Astellas Pharma?

The current dividend yield of Astellas Pharma is 4.67 %.

When does Astellas Pharma pay dividends?

Astellas Pharma pays a quarterly dividend. This is distributed in the months of October, April, October, April.

How secure is the dividend of Astellas Pharma?

Astellas Pharma paid dividends every year for the past 23 years.

What is the dividend of Astellas Pharma?

For the upcoming 12 months, dividends amounting to 73.66 JPY are expected. This corresponds to a dividend yield of 4.78 %.

In which sector is Astellas Pharma located?

Astellas Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Astellas Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Astellas Pharma from 12/1/2024 amounting to 37 JPY, you needed to have the stock in your portfolio before the ex-date on 9/27/2024.

When did Astellas Pharma pay the last dividend?

The last dividend was paid out on 12/1/2024.

What was the dividend of Astellas Pharma in the year 2023?

In the year 2023, Astellas Pharma distributed 65 JPY as dividends.

In which currency does Astellas Pharma pay out the dividend?

The dividends of Astellas Pharma are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Astellas Pharma stock can be added to a savings plan with the following providers: Consorsbank

Andere Kennzahlen von Astellas Pharma

Our stock analysis for Astellas Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Astellas Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.